Tue, Sep 16, 2014, 9:00 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • dean4614 dean4614 Jun 14, 2013 6:01 PM Flag

    From Aetna website

    The past few months have seen the approval of a pair of new drugs designed to treat obesity, Arena’s Belviq (see new now next in diaTribe #44) and Vivus’ Qsymia (see new now next in diaTribe #45). While Belviq is slated to launch in early 2013, Qsymia launched this past September (see new now next in diaTribe #47), and monthly costs for Qsymia range from $120 to $184, depending on the dose. Because Medicare and more than two-thirds of private insurers are not currently covering weight-management medications, the expectation is that most potential users of Qsymia – and eventually Belviq – will need to pay out of pocket.

    Some potentially good news on that front came on November 21, as Aetna announced that it would begin covering weight management drugs in certain patients. This announcement does come with several important caveats, not least of which is that many Aetna plans specifically exclude any obesity medications, and so neither Qsymia nor Belviq would be covered on those plans. However, Aetna members whose plans do allow for weight-loss drugs will be able to get coverage for either Qsymia or Belviq if (1) their BMI is greater than 30 kg/m2 or greater than 27 kg/m2 with one of five risk factors (coronary heart disease, high cholesterol, hypertension, sleep apnea, and type 2 diabetes); and (2) if they have failed to lose at least a pound per week after six months on a weight loss regimen. We think both points will be true for lots of patients and would encourage readers who would like to lose weight to look into it by calling their health insurance plans to inquire what their coverage is for obesity treatments. Specifically, those interested in the Aetna’s update can read it here.

 
ARNA
3.92+0.01(+0.26%)Sep 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.